Clinical Trials Logo

Filter by:
NCT ID: NCT05352321 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Through a prospective clinical trial, we intend to combine surgery, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly diagnosed resectable nasopharyngeal carcinoma to illuminate whether combined surgery could bring patients better local-regional control and lower adverse reactions.

NCT ID: NCT05352269 Recruiting - Clinical trials for Acute-graft-versus-host Disease

Safety and Tolerability of FMT Capsules in Healthy Volunteers

Start date: April 21, 2022
Phase: Phase 1
Study type: Interventional

This is a two-part, randomized, double-blind, placebo-controlled, single center study to investigate the safety and tolerability of XBI-302 administered orally in healthy volunteers. The hypothesis of this study is that XBI-302 is safe and well tolerated with the proposed dosing regimens.

NCT ID: NCT05352152 Recruiting - Liver Diseases Clinical Trials

Application of NGS in Ascites Infection

Start date: July 1, 2022
Phase:
Study type: Observational

Liver cirrhosis is a common serious chronic disease. There are about 123 million patients with liver cirrhosis worldwide, and about 1 million people die of liver cirrhosis every year. The proportion of bacterial infection in hospitalized patients with liver cirrhosis is between 25% and 46%, among which spontaneous bacterial peritonitis (SBP) is the most common type of infection in patients with liver cirrhosis. After early and reasonable diagnosis and treatment, the mortality of cirrhotic patients with SBP can be reduced from more than 90% to about 20%. Therefore, rapid and accurate diagnosis is of great help to improve the prognosis of cirrhotic patients with SBP. However, at present, the traditional detection methods is time-consuming with a low detection rate, and can not detect intracellular bacteria and some other types of pathogens. Next-generation sequencing (NGS) is a relatively new detection technology which can detect the nucleic acid sequence information in a high-throughput, large-scale way. It can detect the pathogens comprehensively, fast and accurately. In recent years, NGS has gradually transitioned from a research tool to a diagnostic method. Many studies have shown that NGS has better application value in bloodstream infections, ocular infectious diseases, central nervous system infectious diseases and respiratory infectious diseases. However, there is still a lack of research on the use of NGS for the detection of pathogenic microorganisms in ascites. Therefore, by comparing the next generation sequence (NGS) and traditional detection technology in the detection of pathogens in ascites, this study aimed to evaluate the value of NGS in the pathogenic diagnosis of ascites infection.

NCT ID: NCT05352074 Recruiting - Surgery Clinical Trials

STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation

Start date: March 27, 2022
Phase: N/A
Study type: Interventional

Total colectomy with ileorectal anastomosis is a traditional surgical option for slow transit constipation. Subtotal colectomy with caecorectal anastomosis is suggested to be a superior approach. However, the optimal surgical option for slow transit constipation (STC) is controversial.

NCT ID: NCT05351788 Recruiting - Clinical trials for Non-small Cell Lung Cancer

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Start date: May 20, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.

NCT ID: NCT05351346 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Genotype-guided Treatment in DLBCL

Start date: June 1, 2022
Phase: Phase 3
Study type: Interventional

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-X) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma

NCT ID: NCT05351320 Recruiting - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Start date: April 30, 2022
Phase: Phase 2
Study type: Interventional

The aim of this trial is to evaluate the safety of WX-0593 combined with concurrent chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer (NSCLC) with activating mutation of ALK or ROS1. This trial consists of two parts. In Part 1, approximately 8 patients will be included and receive WX-0593 maintenance until disease progression or unacceptable toxicity. In Part 2, approximately 32 patients will be included and receive WX-0593 monotherapy for 1-2 cycles and subsequently with concurrent chemoradiation, followed by WX-0593 maintenance until disease progression or unacceptable toxicity.

NCT ID: NCT05351268 Recruiting - Thoracic Cancer Clinical Trials

3DPCT Combined With CT Guided RISI in the Treatment of Thoracic Malignant Tumors

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The main technical difficulties in radioactive iodine-125 seed implantation (RISI) lie in the complexity of operation and the control of operation quality. The current data shows that under the combined guidance of 3D-printing template and CT, the accuracy of RISI has been significantly improved, and the actual target dose could meet the design requirements of preoperative plan. At present, 3D printing templates (3DPT) are divided into non-coplanar templates (3DPNCT) and coplanar templates (3DPCT). In clinical practice, due to the complex technical requirements, high production cost and long printing time of 3DPNCT, a considerable number of patients can also complete the treatment with 3DPCT. Moreover, compared with 3DPNCT, 3DPCT has the advantages of accurate needle path control, fast needle path adjustment, convenient for intraoperative real-time optimization, without waiting for printing time, easy for doctors to master, lower cost than 3DPNCT, and easy to carry out at the grass-roots level. Therefore, this study intends to explore 3DPCT technology to further clarify: (1) the accuracy of 3DPCT assisted CT guided RISI in the treatment of thoracic malignant tumors; (2) the short-term efficacy and toxicity of 3DPCT assisted CT guided RISI in the treatment of thoracic malignant tumors.

NCT ID: NCT05351216 Recruiting - Clinical trials for Kaposiform Hemangioendothelioma

The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma

Start date: March 1, 2021
Phase:
Study type: Observational

To research and explore the antibody protection and immune memory after vaccination in children with KHE during sirolimus administration. To explore the feasibility (safety and efficacy) of vaccination in a timely manner during the administration of sirolimus in children with KHE. To search for back-up plans for vaccination regimens for KHE patients taking sirolimus in children who do not respond to primary vaccination.

NCT ID: NCT05351073 Recruiting - Acute Stroke Clinical Trials

The Prehospital Administration of Normobaric Oxygen in Suspected Stroke

NO SUSPENSION
Start date: January 21, 2022
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to explore the feasibility and safety of normobaric oxygen therapy (NBO) under pre-hospital condition in patients with suspected stroke.